
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries is expected to achieve substantial revenue growth, with projected sales for Ajovy hitting $785 million in 2026, representing a 17% year-over-year increase, and Uzedy anticipated to reach $278 million, reflecting a remarkable 45% growth year-over-year. The company's strong performance in the market is further evidenced by Ajovy’s global revenues of $211 million, which exceeded expectations by 19%, driven by volume gains and improved pricing strategies. With ongoing shifts towards higher-value products and projected net savings of $700 million by 2027, Teva is well-positioned for significant expansion in cash flows and overall financial performance.
Bears say
Teva Pharmaceutical Industries faces significant challenges that contribute to a negative outlook, primarily driven by expected revenue declines due to inventory management and pricing pressures ahead of the Inflation Reduction Act (IRA) implementation. The company's generics segment reported a revenue miss of 3%, with a notable decline in US total prescriptions, indicating persistent market difficulties, while Austedo sales projections suggest a decline in 2027 despite earlier growth. Additionally, the company’s net debt remains a concern, with a ratio of 2.5x EBITDA alongside ongoing risks related to regulatory uncertainties, litigation, and the potential failure of pipeline initiatives.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares